It was a pleasure to speak to Steve Shak from Exact Sciences anto discuss the real-world evidence from a prospective clinical survey of the Oncotype DX Breast Recurrence Score® test, accepted at the ASCO Annual Meeting. Oncotype DX is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
1. Could you give us a brief description of the Oncotype DX Breast Recurrence Score assay and its role in guiding breast cancer treatment decisions? (0:06)
2. Could you summarise the data that its being presented at this year’s ASCO conference? (1:10)
3. What has been the impact of the Oncotype DX test on clinical practice worldwide? (2:21)
4. What progress has been made on making the Oncotype DX test available on a broader international scale? (4:30)
5. What advances do you expect to see in the future with these types of biomarker assays? (7:00)
Speaker disclosure: Steve Shak is Chief Medical Officer of Exact Sciences
Support: Interview and filming supported by Touch Medical Media. Commissioned in liaison with W2O Group.
Filmed in coverage of the 2020 ASCO Virtual Scientific Program.
Related Videos In Breast Cancer
Priyanka Sharma, ASCO20: New Combination Therapy in the Treatment of Triple-Negative Breast Cancer
Priyanka Sharma, University of Kansas, joins us to discuss the data from the SWOG S1416 study (Clinicaltrials.gov identifier: NCT02595905) presented at the ASCO20 Virtual Scientific Programe on the combined use of PARP inhibitors and chemotherapy in the treatment of triple-negative breast cancer. Questions 1. What are the major unmet needs in the treatment of triple-negative […]
Anna van der Voort, ASCO20: Three-year Follow-up of the TRAIN-2 Phase III Trial
We were delighted to speak to Dr Anna van der Voort, The Netherlands Cancer Institute, to discuss her presentation at the ASCO20 Virtual Scientific Program on the long-term follow-up data of the randomised, multicentre, open-label phase III TRAIN-2 trial (ClinicalTrials.gov Identifier: NCT01996267). Questions 1. What are the major unmet needs in current neoadjuvant chemotherapy regimes […]
Javier Cortes, ASCO20: Key findings of the KEYNOTE-355 study
touchONCOLOGY were delighted to speak to Javier Cortes to discuss the key findings of the KEYNOTE-355 study, a randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Questions 1. What are the challenges in the treatment of triple-negative breast cancer? (0:06) 2. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!